Streamlining Radioembolization for CCC and Metastatic Liver Cancer
Recruiting
Observational Study
Metastatic Colorectal Carcinoma (mCRC)
Metastatic Liver Cancer
Cholangiocarcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Seoul National University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage. However, some microspheres may drain into hepatic veins and reach the lungs, risking radiation pneumonitis. Pre-procedural evaluation with angiography and nuclear imaging (MAA scan with SPECT/CT) is required to calculate lung shunt fra…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult aged 19 and over
* metastatic liver cancer or cholangiocarcinoma
* the diameter of the largest tumor ≤ 7cm, tumor number 5 or less
* FLR volume \> 30% of total non-tumorous liver volume
* Dysmorphic intratumoral vessel : absent, if present, 3mm or…
Contacts